BRAF and melanoma: For example, targeting oncogenic BRAF with PLX4720 or PLX4032 resulted in inhibition of growth and invasion of 3D spheroids and caused tumor regression of melanoma xenografts [6,7], which was mirrored in phase II and phase III patient trials and has finally lead FDA-approval of vemurafenib [4,26].